Sulfasalazine-induced pulmonary disease.
We report the findings in two patients with sulfasalazine-induced pulmonary disease. The first patient developed pulmonary interstitial fibrosis after more than 4 yr of treatment for Crohn's disease. Pulmonary symptoms and chest roentgenographic and pulmonary function abnormalities gradually reversed after stopping the drug. No specific treatment was given. The second patient, who had rheumatoid arthritis without pulmonary disease, received the drug for 1 yr without experiencing any problems. Readministration seven months later resulted in the development of an acute interstitial pulmonary disease. Discontinuing the drug and treatment with corticosteroids produced rapid improvement. We discuss these patients in relation to other reports of sulfasalazine-induced pulmonary toxicity, highlighting their atypical features.
Hamadeh
M A
MA
Department of Medicine, Northwestern University, Chicago.
Atkinson
J
J
Smith
L J
LJ
D000208:Acute Disease; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D012460:Sulfasalazine / Q000009:adverse effects*; D013997:Time Factors
D012460:Sulfasalazine